Although transfusion is a lifesaving intervention, it may be associated with significant morbidity in injured patients. We hypothesize that stored red blood cells (RBCs) induce proinflammatory activation of human pulmonary microvascular endothelial cells (HMVECs) resulting in neutrophil (PMN) adhesion and predisposition to acute lung injury (ALI).
the release of proteolytic enzymes from granules resulting in PMN-mediated endothelial damage, capillary leak, and organ injury. 4, 5 Although it is a lifesaving intervention, the transfusion of stored red blood cells (RBCs) has been linked to increased morbidity and mortality in the critically ill. [6] [7] [8] [9] [10] [11] [12] [13] Injured patients, irrespective of the mechanism-blunt, penetrating, or a combination of the two-are prone to acute lung injury (ALI) and the acute respiratory distress syndrome (ARDS). [10] [11] [12] Postinjury ALI and ARDS are postulated to be the result of at least two clinical insults, as demonstrated in animal models. [10] [11] [12] In a prospective study, controlled for the amount of blood transfused, transfusion of stored RBCs, versus fresh, was an independent predictor for the development of ALI and multiple organ failure (MOF) in injured patients. 11 Similar data were found using prestorage leukoreduced RBCs (LRRBCs) such that the transfusion of older, stored LR-RBCs was associated with increased mortality. 10, 14 Despite the incidence of postinjury MOF declining, ALI and ARDS remain significant causes of morbidity and mortality with 64% of severely injured patients developing ALI with 46% progressing to ARDS. 15 Thus, the injury itself plus the transfusion of stored RBCs appear to comprise the first event associated with the development of postinjury ALI or ARDS. During routine storage of LR-RBCs, proinflammatory lipids accumulate, which prime PMNs and can serve as the second event in two-event PMN-mediated animal models of ALI. 4, 5, 16 Therefore, we hypothesize that the supernatant from stored RBCs causes proinflammatory activation of human pulmonary microvascular endothelial cells (HMVECs) and predisposes patients to ALI.
MATERIALS AND METHODS

Materials
Unless otherwise indicated all chemicals were purchased from Sigma Chemical Corp. Buffers were made from sterile water or 0.9% saline for human injection (Baxter Healthcare Corp.) and sterilely filtered. 16 Arachidonic acid (AA), 5-hydroxyeicosotetranoic acid (5-HETE), 12-HETE, and 15-HETE and antibodies to the leukotriene B4 receptor-1 (BLT1) and BLT2 were purchased from Cayman Chemical; siRNA oligo duplexes and Accell siRNA agents were obtained from Dharmacon, Inc. Antibodies for immunoblots and immunoprecipitations were purchased from Santa Cruz Biotechnology. Enzyme-linked immunosorbent assays (ELISAs) for interleukin (IL)-8 were obtained from R&D Systems.
Isolation of blood components
After informed consent was obtained through a protocol approved by the Colorado Multi-Institutional Review Board, 1 unit of whole blood was collected from 20 healthy donors, per industry standards (AABB/FDA). Plasma was separated from RBCs by centrifugation followed by expression, employing an automated closed system (Compomat G4, Fresenius-Kabi), and additive solution-5 (AS-5, Optisol) or AS-3 (Haemonetics) was added to a final hematocrit (Hct) of 60% to 65%. The estimated amount of residual plasma was 5 to 10 mL/unit based on values previously published. 17 For the RBC units stored in AS-5, 50% of each unit was prestorage leukoreduced via filtration with a leukoreduction filter (BPF4, Haemonetics) by weight with the other 50% left unmodified (RBCs). The 10 AS-3-stored RBC units were separated from whole blood and prestorage leukoreduced. The Hct levels ranged from 58% to 65%. The RBCs and LR-RBCs were stored at 1 to 68C, and sterile couplers were used to obtain samples on day (D)1, D14, D21, and D42 (the last day a unit can be transfused) from the RBC and LR-RBC units. The supernatant was isolated via centrifugation (5000 3 g for 7 min) followed by a second centrifugation at 12,500 3 g for 5 minutes to remove platelets (PLTs) and cellular debris. 16 Apheresis PLT concentrates (PCs) were collected from healthy donors using an apheresis device (Trima, Terumo) per industry standards, samples were obtained via sterile couplers, and the supernatant was isolated as described. Before use in tissue culture or in vivo the plasma controls or the supernatants from all cellular components were heated to 568C for 30 minutes to obviate human complement and fibrinogen and in the tissue culture experiments, heparin (10 units/mL) was added in selected experiments, to prevent activation of the clotting cascade. 4 
Lipid extractions
Lipids were extracted from the supernatants of the RBCs and resuspended in the identical starting volume of either 1.25% fatty acid-free human albumin (albumin) for HMVEC experiments or hexane-isopropanol-water for high-performance liquid chromatography (HPLC) separation. 16, 18, 19 Lipids were separated by reverse-phase HPLC developed for phospholipid class separation, and the individual fractions were dried and resuspended in 1.25% albumin and assayed for their ability to activate HMVECs. 4, 5, 16, 18 Proinflammatory HMVEC activation Isolated PMNs were added to HMVECs and allowed to adhere for 60 minutes, and adherence was measured as described. 5 
PMN isolation
Blood was collected from healthy volunteers using informed consent under a protocol approved by the Colorado Multi-Institutional Review Board. The PMNs were isolated as previously described. 16 siRNA knock down of BLT2
Knockdown of BLT2 in HMVECs was done as previously reported. 20 Transfections were completed 72 hours before functional assays were performed.
Immunoblotting and immunoprecipitation
HMVECs were stimulated with the D1 or D42 LR-RBC plasma and the individual NLs at D1 and D42 concentrations for 1 to 15 minutes. The medium was removed, HMVECs were lysed with 1% Triton, and the lysates were saved for immunoprecipitations. A bicinchoninic acid protein assay was completed to ensure that equivalent amounts of protein were loaded, followed by immunoblotting and immunoprecipitations as described.
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A two-event in vivo model of ALI Male Sprague-Dawley rats (Harlan) were treated via a protocol approved by the Institutional Animal Care and Use Committee, University of Colorado at Denver. 4 After anesthesia and cannulation of the femoral vessels, 10% of the blood volume was removed and the animals were infused with an identical volume of saline, heat-treated plasma from D1 or D42 LR-RBCs, or the NLs in human serum albumin. After 6 hours, rats were injected intravenously (IV) with lipopolysaccharide (LPS; 100 mg/kg), and returned to their cages for 2 hours. Blood was drawn, the rats were euthanized, and a bronchoalveolar lavage was performed to measure the Evans Blue dye (EBD) leak. 4 
Statistical analysis
The data are presented as the mean 6 the standard error of the mean (SEM) and were analyzed with independentor repeated-measures ANOVA with a post hoc Bonferroni or Newman-Keuls test for multiple comparisons based on the equality of variance. (Table 2 ). Final concentrations of 20 and 40% also induced significantly increased surface expression of ICAM-1 versus D1 and media controls ( Table 2 ). The HMVEC ICAM-1 surface expression was durable (24 hr) and was not significantly increased compared to the 6-hour incubations (D42 RBC supernatant at 24 hours-10%, 20.4 6 3.8; 20%, 27.0 6 4.6 vs. 6 hours-10%, 21.3 6 3.4; 20%, 34.6 6 1.3; p > 0.05, n 5 8). Lesser concentrations (1%-5%) of D42 RBCs or LR-RBCs or incubation times shorter than 6 hours did not affect ICAM-1 surface expression, and heparinized RBC supernatants elicited similar results (data not shown).
RESULTS
In addition, the supernatants from D42 RBCs and D21 and D42 LR-RBCs, but not D1, caused significant release of IL-8 and increased PMN adhesion at final concentrations of 10% to 40% versus D1 and media controls ( Table 2) .
Lipids from D42 RBCs and LR-RBC activated HMVECs
The lipid extracts from the D42 RBC supernatants at [10, 20, and 40%] FINAL significantly increased ICAM-1 surface expression on HMVECs compared to the media, albumin, and the lipids from both plasma and D1 LR-RBCs (p < 0.05; Table 2 ). These lipid extracts also caused significant release of IL-8 and PMN adhesion versus D1 extracts and albumin-treated controls ( Table 2) . The lipids from D42 LR-RBC units were separated by normal-phase HPLC. The individual fractions, solubilized in 1.25% albumin, were incubated with HMVECs at a final concentration of 10%. Only Fraction 2 demonstrated increased surface expression of ICAM-1 on HMVECs by 2.3-fold versus media controls and Fractions 1 and 3 to 14 (data not shown). Fraction 2, the void volume from normal-phase HPLC, contains the NLs, which are not retained on the column, were then run on reverse-phase HPLC and found to elute at the retention time of the controls, namely, AA and 5-, 12-, and 15-HETE (results not shown). 16 These lipids were further identified by gas chromatography-quadrupole tandem mass spectroscopy and the purified lipids were combined at the concentrations present in the average of 10 units of D42 LR-RBCs and added to HMVECs at a concentration identical to that [10%-20%] FINAL of the supernatant. 16, 22 These purified lipids caused significant increases in ICAM-1 surface expression on HMVECs versus albumintreated controls (Table 2 ). In contrast, lysophosphatidylcholines, which prime PMNs and also accumulate during routine storage of PCs and unmodified RBCs, did not increase ICAM-1 surface expression (Table 1) . BAPTA-AM, a rapid intracellular Ca 21 chelator, also inhibited the D42-mediated increase in ICAM-1 surface expression by 98 6 4% through eliminating the increases in cytosolic Ca 21 ( Fig. 2) . 23 Silencing of BLT2 decreased ICAM-1 surface expression
Extracts of PMNs (positive controls) and HMVECs demonstrated immunoreactivity for both BLT1 and BLT2 (Figs. 3A and 3B). The siRNA oligo sequences to BLT2 (siBLT2) selectively reduced BLT2 immunoreactivity in HMVECs (Fig. 3C ). In addition, silencing of BLT2 inhibited the D42 LR-RBC supernatant [20%] FINAL -mediated increase in ICAM-1 surface expression by 52 6 8% versus HMVECs treated with nontargeting siRNA (n 5 5 for both ICAM-1 and adherence, p < 0.05).
D42 LR-RBC supernatant and the NL mixture may serve as the first event in a two-event, in vivo model of ALI Rats infused with 10% supernatant or purified lipids from D1 LR-RBCs or saline, incubated for 6 hours and then given IV saline or 100 mg/kg of LPS IV, did not develop ALI (Fig. 4) . In addition, rats infused with 10% supernatant or purified lipids from D42 LR-RBCs, incubated for 6 hours and given IV saline, did not evidence ALI. However, rats infused with 10% supernatant or lipids from D42 LRRBCs, incubated for 6 hours and infused with 100 mg/kg LPS, demonstrated significant EBD leak consistent with ALI (Fig. 4) . two-event rodent model of ALI demonstrating possible clinical ramifications for the transfusion of stored LRRBCs. The presented data differ from other studies of endothelial activation in that primary HMVECs were employed. HMVECs express both the BLT1 and the BLT2 receptors on their surface and increase ICAM-1 and release chemokines in response to proinflammatory stimuli resulting in PMN adhesion. 20, [24] [25] [26] [27] [28] Previous data demonstrated that leukotriene B4-mediated HMVEC activation occurred via the BLT2 receptor in congruence with the presented data, and the BLT2 receptor has been implicated in other pulmonary diseases and angiogenesis. 20, [29] [30] [31] Furthermore, the concentration of LPS employed as a positive control may also seem excessive; however, it is based on the human response to injected LPS in which concentrations of 10 ng/mL injected induced hypotensive shock and a concentration of 500 ng/mL induced both shock and signs of ALI and not just fevers and changes in cytokine profiles. [32] [33] [34] The percentage of PMNs that adhered to the activated HMVECs may appear low, but these assays inverted the tissue culture plates (with the adherent cells) and centrifuged them at 200 3 g for 10 minutes; thus, firm PMN adherence is required to remain adherent after exposure to centripetal acceleration of 200 3 g. The animal model of ALI employed has been published multiple times and requires a first event that elicits proinflammatory activation of the pulmonary endothelium, resulting in PMN adherence followed by a second event, which activates these primed, adherent PMNs. 4, 35, 36 In the presented data the infusion of RBC supernatant or the NLs was substituted for LPS as the first event, and LPS was employed as the second event. 4, 35, 36 This animal model has demonstrated ALI via five different types of measurements, which correlate with lung leak as quantified by EBD. 4 The D42 RBC supernatants, the lipid mixture, and the purified lipids caused coprecipitation of the BLT2 receptor with b-arrestin-1. Ligand occupancy of G-protein-linked cellular receptors initiated cellular signaling through recruitment of b-arrestins and other mediators with barrestins responsible for both transduction and termination of signaling events from the activated receptor.
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The b-arrestin-1 scaffold also allows for the interaction of the classical PKC isozyme PKCbI and the nonclassical PKC isoform PKCd to become activated and propagate the signal to increase ICAM-1 surface expression possibly through NFjB, although activation of this transcription factor has not been reported downstream of PKC in HMVECs. There are little data to assume that the NLmediated increases in ICAM-1 surface expression are downstream of the Nox proteins. The BLT2 receptor also has not been linked to Nox proteins in endothelium, although endothelial Nox proteins are linked to organ invasion by Pseudomonas aeruginosa or cancer cells and HNA-3a antibody-induced transfusion-related ALI (TRALI); however, RBC supernatant alone did not induce ALI. 31, [40] [41] [42] [43] [44] Clinical studies of injured patients have determined that blood transfusion is an independent predictor of the development of postinjury MOF and that the infusion of older, stored RBC units correlated with the development of ALI and/or MOF, which was unaffected by leukoreduction. [10] [11] [12] [13] A secondary analysis of the Age of Blood Evaluation (ABLE) trial suggested a "volume-dependent, threshold effect of prolonged red cell storage" such that "further studies on the effect of RBC unit storage age should be focused on patients anticipated to require more than 5 RBC transfusions." 45 In addition, numerous investigators have concluded that the resuscitation of injured patients with older, stored RBC units may result in increased mortality, infections, ALI or ARDS, and postinjury MOF, and such clinical complications may be due to the numbers of units transfused and the "dose" of proinflammatory agents in the stored RBCs. 6, 10, 11, 14, [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] The presented in vitro and in vivo studies of proinflammatory activation of HMVECs by stored RBCs or LR-RBCs support these observations, and it is important to note that such activation only occurred with the transfusion of ">4," ">8," and ">16" units of RBCs, depending on the weight of the patient and their inherent plasma volume, analogous to the final concentration of 10% to 40% of D42 LR-RBC supernatant. These lipids increase during routine storage and large to massive transfusions may allow for exposure to large concentrations of LR-RBC supernatants and the NLs that they contain. NLs accumulate in the supernatant during the routine storage of both RBCs and LR-RBCs and have inherent proinflammatory activity, which changes the cellular physiology of both the vascular endothelium and the circulating granulocytes. 16 Conversely, only lysophosphatidylcholines accumulate in PCs and unmodified RBCs and not in LR-RBCs, indicating that their source is likely the PLT because prestorage leukoreduction also removes PLTs. 16, 36, 70 The NLs are generated through the action of an atypical phospholipase, peroxiredoxin-6, which is released and increased during storage of RBCs or LR-RBCs and is active via Tphosphorylated (T177). This releases AA and 5-lipoxygenase, which converts 5-hydroperoxyeicosatetraenoic acid to 5-HETE, [70] [71] [72] and although leukotrienes are downstream of 5-hydroperoxyeicosatetraenoic acid, the leukotriene synthase to produce LTA 4 and the LTA 4 hydrolase do not accumulate during RBC storage, like both peroxoredoxin-6 and 5-LO. 71 Importantly, there were no leukotrienes, except the HETEs, found by mass spectroscopy, and leukoreduction of RBC units removes the major white blood cell sources of leukotriene B4 and the cysteinyl leukotrienes, with the few short-lived granulocytes rapidly (days) becoming apoptotic. Experimental filtration with a leukoreduction filter that also removed 2 logs of IgG also decreased the production of 5-HETE, the relative amount of lipid-priming activity, and the ability of stored RBC supernatant to induce ALI as the second event. 36 This decrease in 5-HETE was due to virtual elimination as demonstrated by Western blotting of two of the enzymes responsible for %-HETE synthesis and accumulation from AA. 36, 70 These enzymes, 5-lipoxygenase-activating protein and 5-lipoxygenase, share 10 and 17% sequence homology with IgG allowing their clearance from the blood by the experimental filter. 36, 70 There may be other proinflammatory mediators (proteins), which elicit proinflammatory activation of the vascular endothelium predisposing injured patients to PMN-mediated organ injury as has been demonstrated in vitro for a-enolase.
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Proinflammatory activation of HMVECs occurred through activation of the BLT2 receptor. There are little data with regard to the physiologic function of BLT2 on endothelium except for vascular endothelial growth factor-induced angiogenesis. 31 Moreover, both the lipid mixture and each individual lipid moiety caused recruitment of b-arrestin-1 to BLT2. 31 Silencing of BLT2 confirmed the importance of the BLT2 receptor in lipid activation of HMVECs. 20, 31 Parallel silencing approaches were employed with HMVECs because they are sensitive to both transfection and viral infections and to ensure that the inhibition was not due to siRNA delivery alone. These data support a physiologic role for the BLT2 receptor in NL-induced proinflammatory activation of HMVECs.
There are a number of limitations in the presented data. Not each and every storage time point was tested for their ability to induce proinflammatory activation of HMVECs; rather, selected storage times were employed which were found to induce PMN priming because we hypothesized that these lipids would have duality in function: the ability to both prime PMNs and activate endothelium, similar to LPS. 5 In addition, AS-1-stored
RBCs and LR-RBCs were not tested. AS-1 (Adsol) and AS-5 (Optisol) are very similar and differ only by minor changes in NaCl, adenine, and mannitol, although AS-1 has more than twofold more dextrose. 74 AS-5-stored
RBCs were compared to AS-3 (Nutricell) because AS-3 contains NaH 2 PO 4 , citric acid, sodium citrate, and the CP2D anticoagulant with less than 50% of the NaCl of either AS-1 or AS-5. "Omics" analyses of RBCs stored in AS-3 have demonstrated that AS-3 preserves RBC function and physiology better than AS-1, AS-5, or even SAGM. 71, [75] [76] [77] [78] [79] [80] Longer storage was required for lipid accumulation in AS-3-stored LR-RBCs. Finally, the twoevent model of ALI employed has been questioned because humans who received endotoxin did not manifest injury when transfused with older, stored blood RBCs. 81, 82 However, the dose of endotoxin (2 ng/kg; 40-50 pg/mL) used in these experiments was much less than the IV doses (1 mg) for the treatment of neurosyphilis, which was completed in most cases without significant mortality. 33, 70, 81, 82 Aside from becoming febrile with a mild increase in the respiratory rate, the subjects were not as ill as the LPS-treated rats. 33, 70, 81, 82 Moreover, LPS does not induce proinflammatory changes in human PMNs and HMVECs at concentrations of less than 20 ng/mL in vitro, which is orders of magnitude higher than the in vivo dosing. 5, 33, 73, 83 These data support prior clinical reports that identified stored RBC transfusion as an independent risk factor for postinjury ALI or ARDS, MOF, infections, and mortality. 10, 11, 14, 49, 50, [53] [54] [55] 57 Changes in RBC storage to decrease the accumulation of proinflammatory compounds in the supernatant are needed. The presented data have illustrated possible adverse events associated with transfusion; however, these data should not detract from the overall positive impact RBC transfusion has made, allowing for surgical intervention, organ transplantation, and increased survival from cancer. 
